---
schema_version: "secwatch.filing_event.v1"
accession: "0001193125-24-002894"
form_type: "8-K"
ticker: "SPRO"
cik: "0001701108"
company_name: "Spero Therapeutics, Inc."
filed_at: "2024-01-05T23:59:59+00:00"
generated_at: "2026-06-07T03:10:54.312024+00:00"
event_type: "other_material"
sentiment: "neutral"
materiality_score: 0.65
calibrated_materiality_score: 0.65
confidence: "high"
source: SEC EDGAR
---

# Spero Therapeutics provides 2024 outlook; cash $76.3M, runway into late 2025; SPR720 Phase 2a data due 2H 2024

## Summary
- Preliminary cash and cash equivalents of $76.3M as of Dec 31, 2023 (unaudited).
- Cash plus $95M in GSK development milestones expected to fund operations into late 2025.
- PIVOT-PO Phase 3 trial of tebipenem HBr for cUTI initiated; target enrollment ~2,648 patients; completion expected 2H 2025.
- SPR720 Phase 2a topline data for NTM-PD expected in second half of 2024.
- Company entitled to $95M in development milestones from GSK, payable in four equal installments over two years.

## SEC filing metadata
- accession: 0001193125-24-002894
- form_type: 8-K
- ticker: SPRO
- cik: 0001701108
- company_name: Spero Therapeutics, Inc.
- filed_at: 2024-01-05T23:59:59+00:00
- event_type: other_material
- sentiment: neutral
- materiality_score: 0.65
- calibrated_materiality_score: 0.65
- confidence: high
- sec_items: 2.02, 7.01, 8.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1701108/000119312524002894/0001193125-24-002894-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1701108/000119312524002894/d901241d8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001193125-24-002894
- JSON: https://secwatch.observer/filing/0001193125-24-002894.json
- Plain text: https://secwatch.observer/filing/0001193125-24-002894.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.